Laboratory of Natural Bioresources, Faculty of Science, Department of Biology, University of Hassiba Ben Bouali, BP 151, 02000 Chlef, Algeria.
Laboratory of Natural Bioresources, Faculty of Science, Department of Biology, University of Hassiba Ben Bouali, BP 151, 02000 Chlef, Algeria.
Steroids. 2020 Mar;155:108574. doi: 10.1016/j.steroids.2019.108574. Epub 2019 Dec 31.
The importance of the present study comes from the lack of sufficient information about the reversibility of the potential hepatic histopathological alterations which may result from anabolic androgenic drugs abuse by "Cycling" protocol. So, the aim of this study is to explore the negative effects of Deca-Durabolin abuse in hepatic function and structure during an administration cycle.
For our purpose, study was performed on 40 male adult mices. Animals were divided into five groups of 8 animals each treated weekly by Deca-Durabolin (nandrolone decanoate) at 30 g/kg of BW during one month (GI); during two months (GII); during three months (GIII); during three months followed by six weeks of treatment discontinuation (GIV) and Control (C). Plasma assay of liver enzymes (ALT and AST) and cytohistological examination to determine the histopathological damage properties of the liver were performed.
Our results showed that the animals supported very well the administrated substance. Our study showed an increase in plasma levels of liver enzymes (ALT and AST) with the duration of treatment accompanied by important degenerative changes in hepatic tissue with peliosis evolution after two months of treatment. These damages worsen again 6 weeks after stopping treatment and ended by the development of hepatic steatosis with increases hepatic distress.
These results ported that the use of AAS with "Cycling" may lead to the development of hepatic steatosis before progressing to more serious pathological liver situations in AAS abusers.
本研究的重要性在于缺乏足够的信息来了解“周期性使用”合成代谢雄激素类药物可能导致的潜在肝组织病理学改变的可逆性。因此,本研究旨在探讨诺龙滥用对肝功能和结构的负面影响。
我们的研究对象是 40 只雄性成年老鼠,将它们分为五组,每组 8 只,每周经口给予 30g/kgBW 的诺龙(癸酸诺龙),持续一个月(GI);两个月(GII);三个月(GIII);三个月后停药 6 周(GIV)和对照组(C)。检测肝酶(ALT 和 AST)的血浆水平,并进行组织细胞学检查,以确定肝组织的组织病理学损伤特征。
我们的结果表明,动物对给予的物质耐受良好。研究显示,随着治疗时间的延长,血浆中肝酶(ALT 和 AST)的水平升高,肝组织出现严重的退行性变化,两个月后出现肝血窦扩张。停药 6 周后,这些损伤再次加重,最终发展为肝脂肪变性,肝组织出现明显的损伤。
这些结果表明,周期性使用 AAS 可能导致 AAS 滥用者出现肝脂肪变性,进而发展为更严重的肝脏病理情况。